These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33743960)

  • 1. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1.
    Huang S; Liao Q; Li W; Deng G; Jia M; Fang Q; Ji H; Meng M
    Bull Cancer; 2021 Apr; 108(4):359-368. PubMed ID: 33743960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
    Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
    Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
    Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
    Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma.
    Zhou Q; Zhang W; Wang Z; Liu S
    BMC Cancer; 2019 Jul; 19(1):731. PubMed ID: 31340767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long non-coding RNA PTTG3P promotes growth and metastasis of cervical cancer through PTTG1.
    Guo XC; Li L; Gao ZH; Zhou HW; Li J; Wang QQ
    Aging (Albany NY); 2019 Mar; 11(5):1333-1341. PubMed ID: 30853662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycolysis related lncRNA SNHG3 / miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance.
    Yao Y; Chen X; Wang X; Li H; Zhu Y; Li X; Xiao Z; Zi T; Qin X; Zhao Y; Yang T; Wang L; Wu G; Fang X; Wu D
    Int J Biol Macromol; 2024 Mar; 260(Pt 2):129635. PubMed ID: 38266860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer.
    Sun F; Wu K; Yao Z; Mu X; Zheng Z; Sun M; Wang Y; Liu Z; Zhu Y
    Aging (Albany NY); 2020 Jun; 12(12):11500-11516. PubMed ID: 32554858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
    Parolia A; Venalainen E; Xue H; Mather R; Lin D; Wu R; Pucci P; Rogalski J; Evans JR; Feng F; Collins CC; Wang Y; Crea F
    Mol Oncol; 2019 May; 13(5):1121-1136. PubMed ID: 30776192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
    Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
    Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
    Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
    J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
    Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
    Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
    Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
    Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
    Rönnau CGH; Fussek S; Smit FP; Aalders TW; van Hooij O; Pinto PMC; Burchardt M; Schalken JA; Verhaegh GW
    World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
    Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
    Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.